C.E.R.A. safety profile: A pooled analysis in patients with chronic kidney disease

Clinical Nephrology

Volumn 73, Issue 2, 2010, Pages 94-103

  Locatelli, F ^a   Mann, J F E ^b   Aldigier, J C ^c   Sanz Guajardo, D ^d   Schmidt, R ^e   Van Vlem, B ^f   Sulowicz, W ^g   Dougherty, F C ^h   Beyer, U ^h  

^a A MANZONI HOSPITAL   (Italy)

^b KfH Kidney Center   (Germany)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OLV HOSPITAL   (Belgium)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

C.E.R.A; Chronic kidney disease; Renal anemia; Safety profile

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ABNORMAL SENSATION; ACUTE CORONARY SYNDROME; ALLERGIC CONJUNCTIVITIS; ANEMIA; ARTICLE; ASTHMA; BACTEREMIA; BLEEDING; BRAIN INFARCTION; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTUSION; CORONARY ARTERY OBSTRUCTION; DECUBITUS; DEEP VEIN THROMBOSIS; DEPRESSION; DERMATOMYCOSIS; DIABETES MELLITUS; DIABETIC FOOT; DRUG SAFETY; EPILEPSY; ESOPHAGUS CANDIDIASIS; FOLIC ACID DEFICIENCY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAND FRACTURE; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART DISEASE; HEART INFARCTION; HEMODIALYSIS; HEPATITIS; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERHIDROSIS; HYPERLIPIDEMIA; HYPERPYREXIA; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INCIDENCE; INFECTION; INFESTATION; INJECTION SITE PAIN; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; LUNG CONGESTION; LUNG EMBOLISM; MEMORY DISORDER; METABOLIC DISORDER; MORTALITY; MUSCULOSKELETAL DISEASE; NECK PAIN; NEOPLASM; NIGHT SWEAT; NUTRITIONAL DISORDER; OVARY CYST; PERIPHERAL EDEMA; PERIPHERAL ISCHEMIA; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; PNEUMONIA; RENAL ANEMIA; RIB FRACTURE; SEIZURE; SEPSIS; SIDE EFFECT; SKIN ABSCESS; SKIN DISEASE; SKIN ULCER; SOFT TISSUE INJURY; SPINE DISEASE; SUDDEN DEATH; TACHYCARDIA; TENDINITIS; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOEMBOLISM; THROMBOSIS; TINEA PEDIS; UNSTABLE ANGINA PECTORIS; VAGINA MYCOSIS; VEIN THROMBOSIS;

EID: 76649125208     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73094     Document Type: Article

References (16)

1. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U; for the BA16285 Study Investigators. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther. 2007; 29: 626-639.
2. de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D, on behalf of the BA16260 study investigators. Continuous erythropoietin receptor activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60: 1687-1696.
3. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Vlem BV, McMahon AW, Kerloëguen C, Beyer U; on behalf of the STRIATA study investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008; 23: 3654-3661.
4. Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008; 81: 63-69.
5. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U, on behalf of the AMICUS study investigators. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007; 50: 989-1000.
6. Levin NW, Fishbane S, Valdés Cañedo F, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D, on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007; 370: 1415-1421.
7. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R; ERA-EDTA ERBP Advisory Board. Anaemiamanagement in patientswith chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009; 24: 348-354.
8. Locatelli F, Villa G, de Francisco ALM, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U; The BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007; 23: 969-979.
9. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesisstimulating agent for the treatment of anemia. Curr Hematol Rep. 2005; 4: 436-440.
10. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006; 368: 947-953.
11. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1: 1211-1215.
12. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U, on behalf of the ARCTOS study investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008; 3: 337-347.
13. MIRCERA® SPC (Summary of Product Characteristics). Available from: URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp? DocumentID=19960 [Accessed 13 November 2008].
14. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, on behalf of the BA16528 study investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007; 67: 306-317.
15. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U; RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008; 28: 280-289.
16. Sulowicz W, Locatelli F, Ryckelynck J-P, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A.maintains stable hemoglobin control in patientswith chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2: 637-646.